Omeros Q1 Revenue at $9.89M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Reports Q1 revenue $9.89M, consensus $10.05M. "The launch of YARTEMLEA has changed the trajectory of Omeros, both operationally and financially," said Gregory A. Demopulos, M.D., Omeros' Chairman and Chief Executive Officer. "We are seeing strong early adoption across transplant centers, expanding formulary access, favorable reimbursement support, and growing physician experience with the first and only approved treatment for TA-TMA. At the same time, our Novo Nordisk transaction has strengthened our balance sheet and accelerated advancement of our pipeline, including next-generation MASP-2 programs, OncotoX-AML, OMS527 for cocaine use disorder under NIDA funding, and our T-CAT platform targeting multidrug-resistant pathogens. The progress achieved this quarter further demonstrates the strength of our science and the value we are creating across Omeros."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.150
Low
36.00
Averages
43.67
High
55.00
Current: 11.150
Low
36.00
Averages
43.67
High
55.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Omeros Reports Strong Q1 2026 Earnings with Positive Cash Flow
- Significant Revenue Growth: Omeros reported gross revenues of $11.1 million and net revenues of $9.9 million from YARTEMLEA product sales in Q1 2026, reflecting approximately 11% gross-to-net adjustments, indicating strong market demand and product uptake.
- Positive Cash Flow: Despite launching YARTEMLEA in mid-January, the company achieved positive cash flow in Q1 and expects to drive overall positive cash flow within 18 months, highlighting the product's market potential and profitability.
- Key Milestones: The company secured $240 million in upfront cash during Q1 and is eligible for an additional $100 million in near-term milestone payments, enhancing financial stability and future investment capacity.
- Market Access Progress: By March 31, 30 unique accounts had ordered YARTEMLEA, with 60% of the top 10 centers receiving P&T committee approval, demonstrating rapid penetration and acceptance of the product in the healthcare market.
See More
Omeros Reports Q1 Revenue Growth Following Drug Launch
- Significant Revenue Growth: Omeros reported first-quarter net product sales of $9.9 million following the U.S. launch of YARTEMLEA, a substantial increase from zero sales in the same period last year, exceeding Wall Street's estimate of $4.11 million, indicating strong market demand for the drug.
- Decline in Operating Expenses: The company's operating expenses fell sharply to $27.3 million from $35.0 million year-over-year, primarily due to reduced research and development spending, which positively impacts Omeros' financial health.
- Positive Market Reaction: Omeros shares rose over 4% in after-hours trading on Wednesday, reflecting investor optimism regarding the company's first commercial revenue, particularly given the strong early adoption of YARTEMLEA across transplant centers.
- Optimistic Future Outlook: Omeros is awaiting a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026, which could provide further growth momentum for the company.
See More
Omeros Q1 Earnings Exceed Expectations
- Strong Earnings Report: Omeros reported a Q1 non-GAAP EPS of -$0.24, beating expectations by $0.15, indicating improved financial performance and boosting investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $9.89 million, exceeding expectations by $5.78 million, primarily driven by YARTEMLEA sales, reflecting increasing market acceptance of its products.
- Sales Performance: For the three months ending March 31, 2026, gross product sales of YARTEMLEA reached $11.1 million, with net sales of $9.9 million, demonstrating strong performance among U.S. wholesalers and solidifying market position.
- Future Outlook: Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027, showcasing the company's confidence in future growth and strategic planning.
See More
Sagimet Biosciences Appoints New Chief Medical Officer
- Executive Change: Sagimet Biosciences Inc. announced the appointment of Andreas Grauer as Chief Medical Officer effective April 20, aiming to enhance the advancement of its FASN inhibitor pipeline and broader clinical development programs.
- Experienced Leader: Andreas Grauer brings over two decades of experience in clinical development, medical affairs, and regulatory strategy, having most recently served as Chief Medical Officer at Omeros Corp., which is expected to provide valuable industry insights to Sagimet.
- Former CMO Support: Eduardo Bruno Martins has retired but will continue to support the company as an external scientific advisor, ensuring continuity of knowledge and smooth progression of ongoing projects.
- Market Reaction: In pre-market trading on Nasdaq, Sagimet Biosciences' stock fell by 0.31% to $6.45, while Omeros' stock also decreased by 0.22% to $13.41, reflecting market caution regarding the executive change.
See More
Omeros Corp's Yartemlea Receives J-Code Support
- J-Code Empowerment: Omeros Corp. announced that its treatment Yartemlea has received a permanent J-code effective July 1, which will simplify claims processing for hospitals and clinics, thereby reducing administrative burdens and accelerating patient access to treatment.
- Positive Market Reaction: Omeros shares have surged approximately 97% over the past 12 months, and are on track for their best week since December, reflecting investor optimism regarding the impact of the J-code on commercial acceleration.
- European Approval Prospects: The company is eyeing approval for Yartemlea from the European Medicines Agency by mid-2026, which could enhance its competitive position in the global rare disease treatment market and expand its international footprint.
- Strategic Collaboration Potential: The asset purchase and licensing agreement with Danish pharmaceutical company Novo Nordisk could yield up to $2.1 billion for Omeros, including milestone payments, highlighting its strategic positioning in the rare blood and kidney disorders space.
See More
Omeros Corporation Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Performance: Omeros Corporation reported a net income of $86.5 million for Q4 2025, a significant turnaround from a net loss of $31.4 million in the previous year, primarily driven by its partnership with Novo Nordisk, highlighting the company's improved profitability.
- Impact of Partnership: The exclusive global rights deal with Danish pharmaceutical giant Novo, valued at up to $2.1 billion, resulted in a net gain of $237.6 million for Omeros, including $240 million in upfront cash, underscoring the market potential in rare disease therapies.
- Non-GAAP EPS Exceeds Expectations: Omeros reported a non-GAAP EPS of $3.14, surpassing consensus estimates by $2.78, reflecting strong financial management and profitability, which further boosts investor confidence.
- Future Development Plans: Omeros anticipates that its newly approved transplant therapy, Yartemlea, will achieve financial self-sustainability by 2026 and aims for positive cash flow by 2027, indicating confidence in future growth and strategic positioning.
See More
Omeros Reports Strong Q1 2026 Earnings with Positive Cash Flow
- Significant Revenue Growth: Omeros reported gross revenues of $11.1 million and net revenues of $9.9 million from YARTEMLEA product sales in Q1 2026, reflecting approximately 11% gross-to-net adjustments, indicating strong market demand and product uptake.
- Positive Cash Flow: Despite launching YARTEMLEA in mid-January, the company achieved positive cash flow in Q1 and expects to drive overall positive cash flow within 18 months, highlighting the product's market potential and profitability.
- Key Milestones: The company secured $240 million in upfront cash during Q1 and is eligible for an additional $100 million in near-term milestone payments, enhancing financial stability and future investment capacity.
- Market Access Progress: By March 31, 30 unique accounts had ordered YARTEMLEA, with 60% of the top 10 centers receiving P&T committee approval, demonstrating rapid penetration and acceptance of the product in the healthcare market.
See More
Omeros Reports Q1 Revenue Growth Following Drug Launch
- Significant Revenue Growth: Omeros reported first-quarter net product sales of $9.9 million following the U.S. launch of YARTEMLEA, a substantial increase from zero sales in the same period last year, exceeding Wall Street's estimate of $4.11 million, indicating strong market demand for the drug.
- Decline in Operating Expenses: The company's operating expenses fell sharply to $27.3 million from $35.0 million year-over-year, primarily due to reduced research and development spending, which positively impacts Omeros' financial health.
- Positive Market Reaction: Omeros shares rose over 4% in after-hours trading on Wednesday, reflecting investor optimism regarding the company's first commercial revenue, particularly given the strong early adoption of YARTEMLEA across transplant centers.
- Optimistic Future Outlook: Omeros is awaiting a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026, which could provide further growth momentum for the company.
See More
Omeros Q1 Earnings Exceed Expectations
- Strong Earnings Report: Omeros reported a Q1 non-GAAP EPS of -$0.24, beating expectations by $0.15, indicating improved financial performance and boosting investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $9.89 million, exceeding expectations by $5.78 million, primarily driven by YARTEMLEA sales, reflecting increasing market acceptance of its products.
- Sales Performance: For the three months ending March 31, 2026, gross product sales of YARTEMLEA reached $11.1 million, with net sales of $9.9 million, demonstrating strong performance among U.S. wholesalers and solidifying market position.
- Future Outlook: Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027, showcasing the company's confidence in future growth and strategic planning.
See More
Sagimet Biosciences Appoints New Chief Medical Officer
- Executive Change: Sagimet Biosciences Inc. announced the appointment of Andreas Grauer as Chief Medical Officer effective April 20, aiming to enhance the advancement of its FASN inhibitor pipeline and broader clinical development programs.
- Experienced Leader: Andreas Grauer brings over two decades of experience in clinical development, medical affairs, and regulatory strategy, having most recently served as Chief Medical Officer at Omeros Corp., which is expected to provide valuable industry insights to Sagimet.
- Former CMO Support: Eduardo Bruno Martins has retired but will continue to support the company as an external scientific advisor, ensuring continuity of knowledge and smooth progression of ongoing projects.
- Market Reaction: In pre-market trading on Nasdaq, Sagimet Biosciences' stock fell by 0.31% to $6.45, while Omeros' stock also decreased by 0.22% to $13.41, reflecting market caution regarding the executive change.
See More
Omeros Corp's Yartemlea Receives J-Code Support
- J-Code Empowerment: Omeros Corp. announced that its treatment Yartemlea has received a permanent J-code effective July 1, which will simplify claims processing for hospitals and clinics, thereby reducing administrative burdens and accelerating patient access to treatment.
- Positive Market Reaction: Omeros shares have surged approximately 97% over the past 12 months, and are on track for their best week since December, reflecting investor optimism regarding the impact of the J-code on commercial acceleration.
- European Approval Prospects: The company is eyeing approval for Yartemlea from the European Medicines Agency by mid-2026, which could enhance its competitive position in the global rare disease treatment market and expand its international footprint.
- Strategic Collaboration Potential: The asset purchase and licensing agreement with Danish pharmaceutical company Novo Nordisk could yield up to $2.1 billion for Omeros, including milestone payments, highlighting its strategic positioning in the rare blood and kidney disorders space.
See More
Omeros Corporation Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Performance: Omeros Corporation reported a net income of $86.5 million for Q4 2025, a significant turnaround from a net loss of $31.4 million in the previous year, primarily driven by its partnership with Novo Nordisk, highlighting the company's improved profitability.
- Impact of Partnership: The exclusive global rights deal with Danish pharmaceutical giant Novo, valued at up to $2.1 billion, resulted in a net gain of $237.6 million for Omeros, including $240 million in upfront cash, underscoring the market potential in rare disease therapies.
- Non-GAAP EPS Exceeds Expectations: Omeros reported a non-GAAP EPS of $3.14, surpassing consensus estimates by $2.78, reflecting strong financial management and profitability, which further boosts investor confidence.
- Future Development Plans: Omeros anticipates that its newly approved transplant therapy, Yartemlea, will achieve financial self-sustainability by 2026 and aims for positive cash flow by 2027, indicating confidence in future growth and strategic positioning.
See More
